Page 16 - Between May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related adverse event was reported in the sacituzumab group. Evidence Rating Level: 1 (Excellent) Study Rundown: In phase 3 of the TROPiCS-02 trial, sacituzumab govitecan demonstrated significant survival benefit versus chemotherapy among patients with hormone-receptor-positive (HR+)

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting...

The Arizona Cardinals just watched one of their local teams win the National League pennant last night, and it should inspire them in the foreseeable future.

Nine people facing charges, according to the District Attorney's Office

A key suspect in the assassination of Haitian President Jovenel Moïse who has been on the run ever since the brazen July 7, 2021, attack in the hills of Port-au-Prince was arrested Thursday in Haiti.